Alpha 2.0
Login Register
» Authors » Maike H M Wientjes

Maike H M Wientjes

Explore the profile of Maike H M Wientjes including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 17
Followers 0
Related Specialties
Rheumatology
General Medicine
Pharmacology
Top 10 Co-Authors
Alfons A den Broeder
Noortje van Herwaarden
Bart J F van den Bemt
Lise M Verhoef
Nathan den Broeder
Annick de Vries
Ronald F van Vollenhoven
Jordy van Huissteden
Gerrit Jan Wolbink
Cornelis Kramers
Published In
Rheumatology (Oxford)
Expert Opin Drug Metab Toxicol
RMD Open
Trials
Ned Tijdschr Geneeskd
Affiliations
Soon will be listed here.
Recent Articles
1.
Dose reduction of rituximab in clinical practice: a retrospective cohort study of rheumatoid arthritis patients in low disease activity on rituximab
Wientjes M, van Huissteden J, van Herwaarden N, Verhoef L, den Broeder A
Clin Exp Rheumatol . 2024 Jul; 42(11):2215-2220. PMID: 39051162
Objectives: To determine the effects of dose reduction of rituximab (RTX) on rheumatoid arthritis (RA) disease activity in clinical practice. Methods: Retrospective cohort study of RA patients using RTX, in...
2.
Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population
Popa C, Opdam M, den Broeder N, van Ballegooijen H, Mulder K, van de Wiel K, et al.
Rheumatology (Oxford) . 2023 Oct; 63(8):2142-2146. PMID: 37796830
Objective: Caution has been advocated recently when using Janus kinase inhibitors (JAKi) in rheumatoid arthritis (RA) patients with an unfavourable cardiovascular risk profile. We aimed to compare the incidences in...
3.
[Methotrexate to prevent progression to rheumatoid arthritis?]
den Broeder A, van Herwaarden N, Wientjes M
Ned Tijdschr Geneeskd . 2023 Mar; 167. PMID: 36920291
The TREAT EARLIER was aimed at testing whether methotrexate could prevent the evolution from clinically suspect arthralgia to Rheumatoid Arthritis. Although the primary outcome was negative, symptoms did improve during...
4.
Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review
Wientjes M, den Broeder A, Welsing P, Verhoef L, van den Bemt B
RMD Open . 2023 Jan; 8(2). PMID: 36597975
Objectives: In this systematic review, we aim to identify laboratory biomarkers that predict response to tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA). Methods: EMBASE, PubMed and...
5.
The added value of predictive biomarkers in treat-to-target strategies for rheumatoid arthritis patients: a conceptual modelling study
Wientjes M, Ulijn E, Kievit W, Landewe R, Meek I, den Broeder N, et al.
Rheumatology (Oxford) . 2022 Dec; 62(8):2700-2706. PMID: 36538875
Objectives: To quantify the additional value of a hypothetical biomarker predicting response to treatment for RA regarding efficacy and costs by using a modelling design. Methods: A Markov model was...
6.
Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximab
Wientjes M, Gijzen T, den Broeder N, Bloem K, de Vries A, van den Bemt B, et al.
Rheumatology (Oxford) . 2022 Jan; 61(10):3974-3980. PMID: 35022672
Objectives: The REDO trial (REtreatment with Rituximab in RhEumatoid arthritis: Disease Outcome after Dose Optimisation) showed that ultra-low-dose rituximab (500 mg or 200 mg) was similarly effective to a 1000 ...
7.
Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
Wientjes M, Atiqi S, Wolbink G, Nurmohamed M, Boers M, Rispens T, et al.
Trials . 2021 Jun; 22(1):406. PMID: 34147123
Background: A substantial proportion of rheumatoid arthritis (RA) patients discontinues treatment with tumour necrosis factor inhibitors (TNFi) due to inefficacy or intolerance. After the failure of treatment with a TNFi,...
8.
Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review
van Herwaarden N, van den Bemt B, Wientjes M, Kramers C, den Broeder A
Expert Opin Drug Metab Toxicol . 2017 Jul; 13(8):843-857. PMID: 28686523
Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) have improved the treatment outcomes of inflammatory rheumatic diseases including Rheumatoid Arthritis and spondyloarthropathies. Inter-individual variation exists in (maintenance of) response to bDMARDs. Therapeutic...